Do Women Lose Less Weight Than Men on GLP-1s?

The large obesity trials were not designed to compare men and women, so the honest answer starts with arithmetic instead of biology.

Do women lose less weight than men on GLP-1 medications? The honest answer is that the large obesity trials were not designed to settle it, so nobody can quote you a reliable sex difference. What is certain is arithmetic: pounds lost track starting weight, so the same percentage makes a bigger number in a bigger body, and men usually start heavier.

What does a trial average actually tell one person?

An average is a statement about a group. It says nothing about which end of the group you will land on.

The STEP trials (NEJM 2021) reported semaglutide 2.4 mg averaging 14.9% of body weight over 68 weeks alongside lifestyle changes, with about one in three participants reaching 20% or more. That second figure is the useful one: at the same dose, in the same protocol, participants finished well above the average and well below it. SURMOUNT-1 (NEJM 2022) reported tirzepatide at the highest studied dose averaging about 20.9% over 72 weeks, with the same wide range behind it. Both trials studied FDA-approved brand products, not compounded formulations. Results vary by individual.

Sex is one variable among many.

Why do men often see a bigger number on the scale?

Size, mostly, and this part is arithmetic. One tenth of 300 pounds is 30 pounds. One tenth of 190 pounds is 19 pounds. Same percentage, two very different numbers on the scale.

Couples who start treatment together run into this constantly. His scale moves faster, hers moves slower, the dose is identical, and it looks to her like the medication is failing. Which is why I ask patients to write the day-one weight down and work in percentages.

Do side effects show up differently in women and men?

What follows is an impression from my own practice, not data. I have not counted cases and I have no chart review to point to. My impression is that nausea, reflux and constipation come up more often, and sooner after a dose increase, in the women I treat. Whether that is biology, a fixed dose meeting a smaller body, or something about the visit itself, I cannot say. I would rather tell you that than guess.

The impression still changes what I do:

• Hold instead of advancing. Another month at the current dose, when symptoms arrive early, is a legitimate plan.
• Get ahead of constipation. Fiber, fluid, magnesium where appropriate, and a specific conversation about bowel habits at every visit. It is the symptom patients are least likely to raise on their own, and a common reason people stop early.
• Protect lean mass from week one. Protein at every meal, resistance training twice a week, written into the plan at the start.
• Check iron, thyroid and sleep. Fatigue has more than one cause and I would rather look than assume.

Should the starting dose be different for women?

Not by sex on paper. FDA-approved GLP-1 labeling does not dose by sex or by body weight, and the titration steps are the same for everyone. Compounded semaglutide and compounded tirzepatide sit elsewhere: not FDA-approved, not identical to the brand versions, and with no FDA-established titration schedule, so pacing there is a prescribing decision.

I used to move patients up on the calendar because the trials did. I stopped. Now I titrate to the lowest dose that produces a steady change in appetite and hold there. The registrational protocols were built to test the drug at its highest studied dose. Ordinary practice can be paced differently.

What risks belong in the conversation before a first dose?

Not only the mild ones. FDA-approved products in this class carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis, gallbladder disease, kidney injury from dehydration during vomiting or diarrhea, and low blood sugar alongside insulin or a sulfonylurea are in the labeling too. Compounded semaglutide and compounded tirzepatide are not FDA-approved and not identical to the brand versions, which does not exempt them from the same class risks. Read the full risk information with a prescriber who knows your history.

This article is education, not medical advice, and reading it does not create a physician-patient relationship.

How do hormones and life stage change the picture?

They change the setting more than the medication. Polycystic ovary syndrome, perimenopause, the postpartum months and the years after menopause each move appetite, insulin sensitivity, sleep and muscle mass. A woman starting at 47 in perimenopause is working against a moving target.

Two things I raise before writing a first prescription. Pregnancy is an absolute contraindication: these medications are not for use while trying to conceive, during pregnancy, or while breastfeeding, and we settle the stopping plan at the first visit. The second is contraception. FDA-approved labeling for tirzepatide advises patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase. Semaglutide labeling does not carry that instruction, though slowed gastric emptying can still affect absorption of oral medications. Raise it before the first dose.

What do we still not know?

A fair amount. Sex-stratified results from these trials are usually secondary analyses, which were not designed to settle differences between groups. We do not know yet whether menstrual cycle phase changes appetite response, whether hormone therapy alters the trajectory, or whether time since menopause matters more than age. I do not have those answers, and I hold the same caution about the idea that one sex responds better to one molecule.

What should a woman do with this information?

Start with the measurement. Day-one weight written down, one weigh-in a week, converted to a percentage. Take a waist measurement too, because body composition can keep improving while the scale sits still.

Then give the plan a real checkpoint.

Twelve weeks at a tolerated dose, with protein and resistance training in place, is usually long enough to see a direction. If the line is flat, the useful question is why: an interacting prescription, a dose that stalled because side effects needed a plan, thyroid function, sleep, sometimes alcohol.

Cost comes up at almost every first visit, so here it is plainly. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to the brand versions. Our compounded semaglutide is $499 per 90 days, which is $166 a month or about $5.50 a day; compounded tirzepatide starts at $699 per 90 days, $233 a month or about $7.70 a day. The initial physician review is $119, one time, covering the doctor review and the prescription if it is approved; medication is billed separately. Dispensing happens through state-licensed compounding pharmacies operating under section 503A after patient-specific and location-specific verification, and only if a prescription is approved and the pharmacy can fulfill it for that patient location, with packaging and shipping confirmed before fulfillment.

Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly. New Hope Weight Loss and Wellness is not affiliated with or endorsed by either company, and the trials cited above studied those FDA-approved brand products, not compounded formulations. Telehealth, prescribing and shipping depend on patient location and are confirmed before any treatment decision.

If a comparison with a partner has you convinced that being a woman is why your number is moving slowly, do the percentage first. It moves the question from what is wrong with me to what the plan needs next.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.